Active Ingredient (In Each Tablet)
Chlorpheniramine maleate 4 mg
The following Structured Product Label (SPL) was submitted to the FDA by Preferred Pharmaceuticals Inc. for the product Allergy (NDC 68788-6951). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient (in each tablet), purpose, uses, do not use, ask a doctor before use if you have, ask a doctor or pharmacist before use if you are, when using this product, if pregnant or breast-feeding,, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Chlorpheniramine maleate 4 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
to make a child sleepy.
taking sedatives or tranquilizers.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
adults and children | 1 tablet every 4 to 6 |
children 6 to under | 1/2 tablet (break tablet in |
children under 6 | do not use this product in |
corn starch, D&C yellow #10 aluminum lake, lactose anhydrous, magnesium stearate, microcrystalline cellulose
(800) 616-2471
MAJOR®
NDC 68788-6951-02
*Compare to the active ingredient in
Chlor-Trimeton® Allergy Tablets
Allergy
Tablets
Chlorpheniramine maleate 4 mg EACH
ANTIHISTAMINE
Relieves:
• Sneezing • Itchy, Watery Eyes
• Itchy Throat • Runny Nose
4 hour
TAMPER EVIDENT: DO NOT USE IF IMPRINTED
SAFETY SEAL UNDER CAP IS BROKEN OR MISSING
*This product is not manufactured or distributed by
MSD Consumer Care, Inc., owner of the registered
trademark Chlor-Trimeton® Allergy Tablets.
50844 REV0213L19412
Distributed by MAJOR® PHARMACEUTICALS
31778 Enterprise Drive, Livonia, MI 48150 USA
Rev. 12/14 Re-order No. 700459 M-17
Repackaged By: Preferred Pharmaceuticals Inc.
* Please review the disclaimer below.